Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 129

1.

The potential of ctDNA analysis in breast cancer.

Tzanikou E, Lianidou E.

Crit Rev Clin Lab Sci. 2019 Nov 1:1-19. doi: 10.1080/10408363.2019.1670615. [Epub ahead of print]

PMID:
31674269
2.

Multicenter Evaluation of Circulating Cell-Free DNA Extraction and Downstream Analyses for the Development of Standardized (Pre)analytical Work Flows.

Lampignano R, Neumann MHD, Weber S, Kloten V, Herdean A, Voss T, Groelz D, Babayan A, Tibbesma M, Schlumpberger M, Chemi F, Rothwell DG, Wikman H, Galizzi JP, Bergheim IR, Russnes H, Mussolin B, Bonin S, Voigt C, Musa H, Pinzani P, Lianidou E, Brady G, Speicher MR, Pantel K, Betsou F, Schuuring E, Kubista M, Ammerlaan W, Sprenger-Haussels M, Schlange T, Heitzer E; Innovative Medicines Initiative CANCER-ID Consortium.

Clin Chem. 2019 Oct 18. pii: clinchem.2019.306837. doi: 10.1373/clinchem.2019.306837. [Epub ahead of print]

PMID:
31628139
3.

Expression pattern of androgen receptors, AR-V7 and AR-567es, in circulating tumor cells and paired plasma-derived extracellular vesicles in metastatic castration resistant prostate cancer.

Strati A, Zavridou M, Bournakis E, Mastoraki S, Lianidou E.

Analyst. 2019 Nov 4;144(22):6671-6680. doi: 10.1039/c9an00999j.

PMID:
31596277
4.
5.
6.

PIK3CA hotspot mutations in circulating tumor cells and paired circulating tumor DNA in breast cancer: a direct comparison study.

Tzanikou E, Markou A, Politaki E, Koutsopoulos A, Psyrri A, Mavroudis D, Georgoulias V, Lianidou E.

Mol Oncol. 2019 Jun 29. doi: 10.1002/1878-0261.12540. [Epub ahead of print]

7.

Multicenter Evaluation of Circulating Plasma MicroRNA Extraction Technologies for the Development of Clinically Feasible Reverse Transcription Quantitative PCR and Next-Generation Sequencing Analytical Work Flows.

Kloten V, Neumann MHD, Di Pasquale F, Sprenger-Haussels M, Shaffer JM, Schlumpberger M, Herdean A, Betsou F, Ammerlaan W, Af Hällström T, Serkkola E, Forsman T, Lianidou E, Sjöback R, Kubista M, Bender S, Lampignano R, Krahn T, Schlange T; CANCER-ID consortium.

Clin Chem. 2019 Sep;65(9):1132-1140. doi: 10.1373/clinchem.2019.303271. Epub 2019 Jun 24.

PMID:
31235535
8.

Surrogates of immunologic cell death (ICD) and chemoradiotherapy outcomes in head and neck squamous cell carcinoma (HNSCC).

Economopoulou P, Koutsodontis G, Strati A, Kirodimos E, Giotakis E, Maragoudakis P, Prikas C, Papadimitriou N, Perisanidis C, Gagari E, Kotsantis I, Vagia E, Anastasiou M, Gkotzamanidou M, Kavourakis G, Lianidou E, Psyrri A.

Oral Oncol. 2019 Jul;94:93-100. doi: 10.1016/j.oraloncology.2019.05.019. Epub 2019 May 28.

PMID:
31178219
9.

HPV16 E6/E7 expression in circulating tumor cells in oropharyngeal squamous cell cancers: A pilot study.

Economopoulou P, Koutsodontis G, Avgeris M, Strati A, Kroupis C, Pateras I, Kirodimos E, Giotakis E, Kotsantis I, Maragoudakis P, Gorgoulis V, Scorilas A, Lianidou E, Psyrri A.

PLoS One. 2019 May 9;14(5):e0215984. doi: 10.1371/journal.pone.0215984. eCollection 2019.

10.

Development and Validation of Multiplex Liquid Bead Array Assay for the Simultaneous Expression of 14 Genes in Circulating Tumor Cells.

Parisi C, Markou A, Strati A, Kasimir-Bauer S, Lianidou ES.

Anal Chem. 2019 Mar 5;91(5):3443-3451. doi: 10.1021/acs.analchem.8b04975. Epub 2019 Feb 11.

PMID:
30663875
11.

Circulating cell-free DNA in breast cancer: size profiling, levels, and methylation patterns lead to prognostic and predictive classifiers.

Panagopoulou M, Karaglani M, Balgkouranidou I, Biziota E, Koukaki T, Karamitrousis E, Nena E, Tsamardinos I, Kolios G, Lianidou E, Kakolyris S, Chatzaki E.

Oncogene. 2019 May;38(18):3387-3401. doi: 10.1038/s41388-018-0660-y. Epub 2019 Jan 14.

PMID:
30643192
12.

Liquid biopsy in ovarian cancer: the potential of circulating miRNAs and exosomes.

Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES.

Transl Res. 2019 Mar;205:77-91. doi: 10.1016/j.trsl.2018.10.003. Epub 2018 Oct 12. Review.

PMID:
30391474
13.

Liquid biopsies.

Lianidou E, Pantel K.

Genes Chromosomes Cancer. 2019 Apr;58(4):219-232. doi: 10.1002/gcc.22695. Review.

PMID:
30382599
14.

A pilot plasma-ctDNA ring trial for the Cobas® EGFR Mutation Test in clinical diagnostic laboratories.

Ntzifa A, Kroupis C, Haliassos A, Lianidou E.

Clin Chem Lab Med. 2019 Apr 24;57(5):e97-e101. doi: 10.1515/cclm-2018-0676. No abstract available.

PMID:
30267626
15.

Evaluation of Preanalytical Conditions and Implementation of Quality Control Steps for Reliable Gene Expression and DNA Methylation Analyses in Liquid Biopsies.

Zavridou M, Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Lianidou E.

Clin Chem. 2018 Oct;64(10):1522-1533. doi: 10.1373/clinchem.2018.292318. Epub 2018 Jul 17.

16.

ESR1 methylation in primary tumors and paired circulating tumor DNA of patients with high-grade serous ovarian cancer.

Giannopoulou L, Mastoraki S, Buderath P, Strati A, Pavlakis K, Kasimir-Bauer S, Lianidou ES.

Gynecol Oncol. 2018 Aug;150(2):355-360. doi: 10.1016/j.ygyno.2018.05.026. Epub 2018 May 26.

PMID:
29807696
17.

ESR1 Methylation: A Liquid Biopsy-Based Epigenetic Assay for the Follow-up of Patients with Metastatic Breast Cancer Receiving Endocrine Treatment.

Mastoraki S, Strati A, Tzanikou E, Chimonidou M, Politaki E, Voutsina A, Psyrri A, Georgoulias V, Lianidou E.

Clin Cancer Res. 2018 Mar 15;24(6):1500-1510. doi: 10.1158/1078-0432.CCR-17-1181. Epub 2017 Dec 28.

18.

A Comparison of Three Methods for the Detection of Circulating Tumor Cells in Patients with Early and Metastatic Breast Cancer.

Politaki E, Agelaki S, Apostolaki S, Hatzidaki D, Strati A, Koinis F, Perraki M, Saloustrou G, Stoupis G, Kallergi G, Spiliotaki M, Skaltsi T, Lianidou E, Georgoulias V, Mavroudis D.

Cell Physiol Biochem. 2017;44(2):594-606. doi: 10.1159/000485115. Epub 2017 Nov 20.

19.

Multiplex Gene Expression Profiling of In Vivo Isolated Circulating Tumor Cells in High-Risk Prostate Cancer Patients.

Markou A, Lazaridou M, Paraskevopoulos P, Chen S, Świerczewska M, Budna J, Kuske A, Gorges TM, Joosse SA, Kroneis T, Zabel M, Sedlmayr P, Alix-Panabières C, Pantel K, Lianidou ES.

Clin Chem. 2018 Feb;64(2):297-306. doi: 10.1373/clinchem.2017.275503. Epub 2017 Nov 9.

20.

Liquid biopsy: An emerging prognostic and predictive tool in Head and Neck Squamous Cell Carcinoma (HNSCC). Focus on Circulating Tumor Cells (CTCs).

Economopoulou P, Kotsantis I, Kyrodimos E, Lianidou ES, Psyrri A.

Oral Oncol. 2017 Nov;74:83-89. doi: 10.1016/j.oraloncology.2017.09.012. Epub 2017 Oct 2. Review.

PMID:
29103757
21.

Direct comparison study of DNA methylation markers in EpCAM-positive circulating tumour cells, corresponding circulating tumour DNA, and paired primary tumours in breast cancer.

Chimonidou M, Strati A, Malamos N, Kouneli S, Georgoulias V, Lianidou E.

Oncotarget. 2017 Jun 27;8(42):72054-72068. doi: 10.18632/oncotarget.18679. eCollection 2017 Sep 22.

22.

Prognostic significance of PD-L1 expression on circulating tumor cells in patients with head and neck squamous cell carcinoma.

Strati A, Koutsodontis G, Papaxoinis G, Angelidis I, Zavridou M, Economopoulou P, Kotsantis I, Avgeris M, Mazel M, Perisanidis C, Sasaki C, Alix-Panabières C, Lianidou E, Psyrri A.

Ann Oncol. 2017 Aug 1;28(8):1923-1933. doi: 10.1093/annonc/mdx206.

PMID:
28838214
23.

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA.

Giannopoulou L, Kasimir-Bauer S, Lianidou ES.

Clin Chem Lab Med. 2018 Jan 26;56(2):186-197. doi: 10.1515/cclm-2017-0019. Review.

24.

Exosomes: A Cancer Theranostics Road Map.

Panagiotara A, Markou A, Lianidou ES, Patrinos GP, Katsila T.

Public Health Genomics. 2017;20(2):116-125. doi: 10.1159/000478253. Epub 2017 Jul 20. Review.

25.

miRNA-21 as a novel therapeutic target in lung cancer.

Markou A, Zavridou M, Lianidou ES.

Lung Cancer (Auckl). 2016 Mar 2;7:19-27. doi: 10.2147/LCTT.S60341. eCollection 2016. Review.

26.

RASSF1A promoter methylation in high-grade serous ovarian cancer: A direct comparison study in primary tumors, adjacent morphologically tumor cell-free tissues and paired circulating tumor DNA.

Giannopoulou L, Chebouti I, Pavlakis K, Kasimir-Bauer S, Lianidou ES.

Oncotarget. 2017 Mar 28;8(13):21429-21443. doi: 10.18632/oncotarget.15249.

27.

Improved detection of circulating tumor cells in non-metastatic high-risk prostate cancer patients.

Kuske A, Gorges TM, Tennstedt P, Tiebel AK, Pompe R, Preißer F, Prues S, Mazel M, Markou A, Lianidou E, Peine S, Alix-Panabières C, Riethdorf S, Beyer B, Schlomm T, Pantel K.

Sci Rep. 2016 Dec 21;6:39736. doi: 10.1038/srep39736.

28.

Development and validation of a multiplex methylation specific PCR-coupled liquid bead array for liquid biopsy analysis.

Parisi C, Mastoraki S, Markou A, Strati A, Chimonidou M, Georgoulias V, Lianidou ES.

Clin Chim Acta. 2016 Oct 1;461:156-64. doi: 10.1016/j.cca.2016.08.003. Epub 2016 Aug 7.

PMID:
27510924
29.

Methylation status of the APC and RASSF1A promoter in cell-free circulating DNA and its prognostic role in patients with colorectal cancer.

Matthaios D, Balgkouranidou I, Karayiannakis A, Bolanaki H, Xenidis N, Amarantidis K, Chelis L, Romanidis K, Chatzaki A, Lianidou E, Trypsianis G, Kakolyris S.

Oncol Lett. 2016 Jul;12(1):748-756. Epub 2016 Jun 1.

30.

Direct Comparison of Metastasis-Related miRNAs Expression Levels in Circulating Tumor Cells, Corresponding Plasma, and Primary Tumors of Breast Cancer Patients.

Markou A, Zavridou M, Sourvinou I, Yousef G, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Chem. 2016 Jul;62(7):1002-11. doi: 10.1373/clinchem.2015.253716. Epub 2016 May 19.

31.

Gene expression profiling and DNA methylation analyses of CTCs.

Lianidou ES.

Mol Oncol. 2016 Mar;10(3):431-42. doi: 10.1016/j.molonc.2016.01.011. Epub 2016 Feb 5. Review.

32.

MicroRNA-194 is a Marker for Good Prognosis in Clear Cell Renal Cell Carcinoma.

Nofech-Mozes R, Khella HW, Scorilas A, Youssef L, Krylov SN, Lianidou E, Sidiropoulos KG, Gabril M, Evans A, Yousef GM.

Cancer Med. 2016 Apr;5(4):656-64. doi: 10.1002/cam4.631. Epub 2016 Feb 10.

33.

SOX17 promoter methylation in plasma circulating tumor DNA of patients with non-small cell lung cancer.

Balgkouranidou I, Chimonidou M, Milaki G, Tsaroucha E, Kakolyris S, Georgoulias V, Lianidou E.

Clin Chem Lab Med. 2016 Aug 1;54(8):1385-93. doi: 10.1515/cclm-2015-0776.

PMID:
26741346
34.

Development of a novel PTT assay for mutation detection in PALB2 large exons and PALB2 screening in medullary breast cancer.

Poumpouridou N, Goutas N, Tsionou C, Dimas K, Lianidou E, Kroupis C.

Fam Cancer. 2016 Apr;15(2):183-91. doi: 10.1007/s10689-015-9851-7.

PMID:
26573693
35.

The Role of CTCs as Tumor Biomarkers.

Lianidou ES, Markou A, Strati A.

Adv Exp Med Biol. 2015;867:341-67. doi: 10.1007/978-94-017-7215-0_21. Review.

PMID:
26530376
36.

Development and validation of molecular methodologies to assess PALB2 expression in sporadic breast cancer.

Poumpouridou N, Acha-Sagredo A, Goutas N, Vlachodimitropoulos D, Chatziioannidou I, Lianidou E, Liloglou T, Kroupis C.

Clin Biochem. 2016 Feb;49(3):253-9. doi: 10.1016/j.clinbiochem.2015.10.009. Epub 2015 Oct 23.

PMID:
26526077
37.

miR-221/222 Are Involved in Response to Sunitinib Treatment in Metastatic Renal Cell Carcinoma.

Khella HWZ, Butz H, Ding Q, Rotondo F, Evans KR, Kupchak P, Dharsee M, Latif A, Pasic MD, Lianidou E, Bjarnason GA, Yousef GM.

Mol Ther. 2015 Nov;23(11):1748-1758. doi: 10.1038/mt.2015.129. Epub 2015 Jul 23.

38.

Prognostic role of APC and RASSF1A promoter methylation status in cell free circulating DNA of operable gastric cancer patients.

Balgkouranidou I, Matthaios D, Karayiannakis A, Bolanaki H, Michailidis P, Xenidis N, Amarantidis K, Chelis L, Trypsianis G, Chatzaki E, Lianidou ES, Kakolyris S.

Mutat Res. 2015 Aug;778:46-51. doi: 10.1016/j.mrfmmm.2015.05.002. Epub 2015 Jun 11.

PMID:
26073472
39.

An integrated genomic analysis of papillary renal cell carcinoma type 1 uncovers the role of focal adhesion and extracellular matrix pathways.

Wala SJ, Karamchandani JR, Saleeb R, Evans A, Ding Q, Ibrahim R, Jewett M, Pasic M, Finelli A, Pace K, Lianidou E, Yousef GM.

Mol Oncol. 2015 Oct;9(8):1667-77. doi: 10.1016/j.molonc.2015.04.007. Epub 2015 May 14.

40.

A rapid and accurate closed-tube Methylation-Sensitive High Resolution Melting Analysis assay for the semi-quantitative determination of SOX17 promoter methylation in clinical samples.

Mastoraki S, Chimonidou M, Dimitrakopoulos L, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Chim Acta. 2015 Apr 15;444:303-9. doi: 10.1016/j.cca.2015.02.035. Epub 2015 Feb 27.

PMID:
25727515
41.

Metastasis-related miRNAs: a new way to differentiate patients with higher risk?

Markou A, Lianidou E, Georgoulias V.

Future Oncol. 2015;11(3):365-7. doi: 10.2217/fon.14.294. No abstract available.

42.

Low expression of miR-126 is a prognostic marker for metastatic clear cell renal cell carcinoma.

Khella HW, Scorilas A, Mozes R, Mirham L, Lianidou E, Krylov SN, Lee JY, Ordon M, Stewart R, Jewett MA, Yousef GM.

Am J Pathol. 2015 Mar;185(3):693-703. doi: 10.1016/j.ajpath.2014.11.017. Epub 2015 Jan 5.

PMID:
25572155
43.

miR-210 is a prognostic marker in clear cell renal cell carcinoma.

Samaan S, Khella HW, Girgis A, Scorilas A, Lianidou E, Gabril M, Krylov SN, Jewett M, Bjarnason GA, El-said H, Yousef GM.

J Mol Diagn. 2015 Mar;17(2):136-44. doi: 10.1016/j.jmoldx.2014.10.005. Epub 2014 Dec 31.

PMID:
25555365
44.

PIK3CA mutational status in circulating tumor cells can change during disease recurrence or progression in patients with breast cancer.

Markou A, Farkona S, Schiza C, Efstathiou T, Kounelis S, Malamos N, Georgoulias V, Lianidou E.

Clin Cancer Res. 2014 Nov 15;20(22):5823-34. doi: 10.1158/1078-0432.CCR-14-0149.

45.

Molecular characterization of circulating tumor cells: Holy Grail for personalized cancer treatment?

Lianidou ES.

Clin Chem. 2014 Oct;60(10):1249-51. doi: 10.1373/clinchem.2014.230144. Epub 2014 Aug 20. No abstract available.

46.

Microenvironmental Influences on Metastasis Suppressor Expression and Function during a Metastatic Cell's Journey.

Liu W, Vivian CJ, Brinker AE, Hampton KR, Lianidou E, Welch DR.

Cancer Microenviron. 2014 Dec;7(3):117-31. doi: 10.1007/s12307-014-0148-4. Epub 2014 Jun 18.

47.

Advancing the education in molecular diagnostics: the IFCC-Initiative "Clinical Molecular Biology Curriculum" (C-CMBC); a ten-year experience.

Lianidou E, Ahmad-Nejad P, Ferreira-Gonzalez A, Izuhara K, Cremonesi L, Schroeder ME, Richter K, Ferrari M, Neumaier M.

Clin Chim Acta. 2014 Sep 25;436:5-8. doi: 10.1016/j.cca.2014.04.031. Epub 2014 May 9.

PMID:
24815033
48.

Breast cancer metastasis suppressor-1 promoter methylation in cell-free DNA provides prognostic information in non-small cell lung cancer.

Balgkouranidou I, Chimonidou M, Milaki G, Tsarouxa EG, Kakolyris S, Welch DR, Georgoulias V, Lianidou ES.

Br J Cancer. 2014 Apr 15;110(8):2054-62. doi: 10.1038/bjc.2014.104. Epub 2014 Mar 18.

49.

Circulating tumor cells as promising novel biomarkers in solid cancers.

Lianidou ES, Strati A, Markou A.

Crit Rev Clin Lab Sci. 2014 Jun;51(3):160-71. doi: 10.3109/10408363.2014.896316. Epub 2014 Mar 19. Review.

PMID:
24641350
50.

Circulating tumor cell isolation: a marathon race worth running.

Lianidou ES.

Clin Chem. 2014 Feb;60(2):287-9. doi: 10.1373/clinchem.2013.216010. Epub 2013 Dec 9. No abstract available.

Supplemental Content

Loading ...
Support Center